Ranibizumab for Macular Edema Secondary to Central and Branch Retinal Vein Occlusion in Patients Younger Than 50 Years of Age

Ranibizumab for Macular Edema Secondary to Central and Branch Retinal Vein Occlusion in Patients Younger Than 50 Years of Age

Background. To determine the effectiveness of intravitreal ranibizumab (IVR) approach over 1-year follow-up in patients younger than 50 years old with central and branch retinal vein occlusion (RVO) complicated by macular edema (ME). Methods. Prospective, open-label case series. Patients initiating...

Full description

Bibliographic Details
Main Authors: Maurizio Battaglia Parodi, Francesco Romano, Alessandro Arrigo, Stefano Mercuri, Alessandro Franceschi, Francesco Bandello
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:BioMed Research International
Online Access:http://dx.doi.org/10.1155/2020/4747696

Internet

http://dx.doi.org/10.1155/2020/4747696

Similar Items